[[Translated article]]Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.

Autores de IIS La Fe

• Daniel Martín Torregrosa

  Autor

• Miguel Mansilla Polo

  Autor

Participantes ajenos a IIS La Fe

• Morgado-Carrasco D

Grupos

• Dermatología y Regeneración Tisular

Abstract

Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.

Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Keywords

• Anifrolumab; Dermatomiositis; Dermatomyositis; Esclerodermia; Lupus; Scleroderma